Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice. What is the most challenging aspect of treating patients with advan...
Continue reading

Nivolumab Proves Effective in Advanced Esophageal Cancer

According to the results of the phase 3 trial, ATTRACTION-3, nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma. For this study, results of which are published in The Lancet Oncology, researchers enrolled 419 patients from 90 hospital and cancer centers in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. Patients with unresectable advanced or recurrent e...
Continue reading

Pembrolizumab for Advanced Esophageal Squamous Cell Carcinoma: An Interview with Ken Kato, MD

On July 30, 2019, the FDA approved pembrolizumab (Keytruda®, Merck) for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus (ESCC) whose tumors expressed a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of at least 10 and whose disease progressed after at least one line of systemic therapy. The approval was based on two clinical trials. One of these was Keynote-181, which enrolled 628 patients with locally advanced or metastatic ESCC w...
Continue reading

Pembrolizumab Approved for Advanced Esophageal Squamous Cell Carcinoma

Pembrolizumab (Keytruda®, Merck) has been approved by the FDA for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus (ESCC) with tumors expressing a programmed death ligand-1 (PD-L1) combined positive score (CPS) of at least 10 and with disease progression following one or more previous systemic treatments. The approval was based on the Keynote-181 (NCT02559687) and Keynote-180 (NCT02564263) clinical trials. Keynote-181 enrolled 628 patients with recu...
Continue reading

[Fam-] Trastuzumab Deruxtecan in Advanced Gastric Cancer With Kohei Shitara, MD

​ Current treatment options are highly limited for patients with advanced human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction cancer, particularly after trastuzumab. A potential new treatment has emerged in a phase 1 clinical trial, which reports that [fam-] trastuzumab deruxtecan shows preliminary activity in patients with heavily pretreated HER2-positive gastric or gastro-esophageal junction cancer. In this interview with i3 Health, Kohei Shitara, MD,...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.